

VII.
Matrix Format – Multiple Primary and Histology Coding Rules

Head and Neck Multiple Primary Rules – Matrix
C000-C148, C300-C329
(Excludes lymphoma and leukemia – M9590 – 9989 and Kaposi sarcoma M9140)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
 ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|---|-----------|--------|----------|---|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMORS | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted. <i>Example 1:</i> History and physical exam states large tumor in nasopharynx. Biopsy base of tongue shows squamous cell carcinoma. No further information available. Abstract as a single primary. <i>Example 2:</i> Pathology report states extensive squamous cell carcinoma involving nasopharynx and larynx. Fragments of epiglottis positive for squamous cell carcinoma. No other information available. Abstract as a single primary. | Single* |
| SINGLE TUMOR | | | | | <i>1:</i> Tumor not described as metastasis <i>2:</i> Includes combinations of in situ and invasive | |
| M2 | Single | | | | The tumor may overlap onto or extend into adjacent/contiguous site or subsite. | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | <i>1:</i> Tumors not described as metastases <i>2:</i> Includes combinations of in situ and invasive | |
| M3 | Right side and left side of a paired site | | | | See Table 1 for list of paired sites | Multiple** |
| M4 | Upper lip (C000 or C003) and lower lip (C001 or C004) | | | | | Multiple** |
| M5 | Upper gum (C030) and lower gum (C031) | | | | | Multiple** |

Head and Neck Multiple Primary Rules – Matrix
C000-C148, C300-C329
(Excludes lymphoma and leukemia – M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|-------------|---|------------------|--|----------------------------------|---|----------------|
| M6 | Nasal cavity (C300) and middle ear (C301) | | | | | Multiple** |
| M7 | Topography codes that are different at the second (C x xx) and/or third (Cx x) character | | | | | Multiple** |
| M8 | | | More than 60 days after diagnosis | An invasive following an in situ | <i>1:</i> The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. <i>2:</i> Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. | Multiple** |
| M9 | | | Diagnosed more than five (5) years apart | | | Multiple** |

Head and Neck Multiple Primary Rules – Matrix
C000-C148, C300-C329
(Excludes lymphoma and leukemia – M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|-------------|-------------|---|---------------|-----------------|-----------------------|----------------|
| M10 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and another is a specific histology; or • Carcinoma, NOS (8010) and another is a specific carcinoma; or • Adenocarcinoma, NOS (8140) and another is a specific adenocarcinoma; or • Squamous cell carcinoma, NOS (8070) and another is specific squamous cell carcinoma or • Melanoma and another is a specific melanoma; or • Sarcoma, NOS (8800) and another is a specific sarcoma | | | | Single* |
| M11 | | Different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number | | | | Multiple** |

Head and Neck Multiple Primary Rules – Matrix
C000-C148, C300-C329
(Excludes lymphoma and leukemia – M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|-------------|---|------------------|---------------|-----------------|---|----------------|
| M12 | Does not meet any of the above criteria | | | | <p><i>1.</i> When an invasive tumor follows an in situ tumor within 60 days, abstract as a single primary.</p> <p><i>2.</i> All cases covered by rule M12 have the same first 3 numbers in ICD-O-3 histologic code.</p> <p>Rule M12 Examples: The following are examples of cases that use Rule M12. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary. Warning: <i>Using only these case examples to determine the number of primaries can result in major errors</i></p> <p>Example 1: Multifocal tumors in floor of mouth</p> <p>Example 2: An in situ and invasive tumor diagnosed within 60 days</p> <p>Example 3: In situ following an invasive tumor more than 60 days apart</p> | Single* |

Head and Neck Histology Coding Rules – Matrix
C000-C148, C300-C329
(Excludes lymphoma and leukemia – M-9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---------------------|--|-----------|----------------------|--|---|
| SINGLE TUMOR | | | | | |
| H1 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of cancer (histology) in the medical record • CT, PET or MRI scans <p>2: Code the specific histology when documented.</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H2 | None from primary site | | | Code the behavior /3 | The histology from metastatic site |
| H3 | | One type | | <p>Example: Squamous cell carcinoma. Code 8070.</p> <p>Do not code terms that do not appear in the histology description.</p> <p>Example: Do not code 8072 (squamous cell carcinoma non-keratinizing) unless the words “non-keratinizing” actually appear in the diagnosis</p> | The histology |
| H4 | | | Invasive and in situ | <p>Example: The final diagnosis is keratinizing squamous cell carcinoma (8071) with areas of squamous cell carcinoma in situ (8070). Code the invasive histologic type, keratinizing squamous cell carcinoma (8071).</p> | The invasive histologic type |

Head and Neck Histology Coding Rules – Matrix
C000-C148, C300-C329

(Excludes lymphoma and leukemia – M-9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|-------------|--------------------------------------|--|-----------------|---|--|
| H5 | | <p>Multiple histologies all within the same branch on Chart 1.</p> <p>Examples of histologies within same banch:</p> <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology or • Carcinoma, NOS (8010) and a more specific carcinoma or • Squamous cell carcinoma, NOS (8070) and a more specific squamous cell carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Melanoma, NOS (8720) and a more specific melanoma or • Sarcoma, NOS (8800) and a more specific sarcoma | | <p><i>1.</i> The specific histology for in situ tumors may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ____differentiation.</p> <p><i>2.</i> The specific histology for invasive tumors may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation.</p> <p>Example: The final diagnosis is squamous cell carcinoma (8070), papillary (8050). Code the specific type, papillary (8050).</p> | The most specific term using Chart 1 |
| H6 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Head and Neck Histology Coding Rules – Matrix
C000-C148, C300-C329
(Excludes lymphoma and leukemia – M-9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--|-----------|----------|---|---|
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H7 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p>I: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of cancer (histology) in the medical record • CT, PET or MRI scans <p>2: Code the specific histology when documented</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H8 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |
| H9 | | One type | | <p>Example: Squamous cell carcinoma. Code 8070.</p> <p>Do not code terms that do not appear in the histology description.</p> <p>Example: Do not code 8072 (squamous cell carcinoma non-keratinizing) unless the words “non-keratinizing” actually appear in the diagnosis</p> | The histology |
| H10 | | | | <p>I: See the Head and Neck Equivalent Terms, Definitions, Charts, Tables and Illustrations for the definition of most invasive.</p> <ul style="list-style-type: none"> • One tumor is in situ and one is invasive, code the histology from the invasive tumor • Both/all histologies are invasive, code the histology of the more invasive tumor. <p>2. If tumors are equally invasive, go to the next rule</p> | The histology of the most invasive tumor |

Head and Neck Histology Coding Rules – Matrix
C000-C148, C300-C329

(Excludes lymphoma and leukemia – M-9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------------|--------------------------------|--|----------|---|---|
| H11 | | <p>Multiple histologies all within the same branch on Chart 1. Examples of histologies within same banch:</p> <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology or • Carcinoma, NOS (8010) and a more specific carcinoma or • Squamous cell carcinoma, NOS (8070) and a more specific squamous cell carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Melanoma, NOS (8720) and a more specific melanoma or Sarcoma, NOS (8800) and a more specific sarcoma | | <p><i>1.</i> The specific histology for in situ tumors may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ____differentiation. <i>2.</i> The specific histology for invasive tumors may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation. Example: The final diagnosis is squamous cell carcinoma (8070), papillary (8050). Code the specific type, papillary (8050).</p> | <p>The most specific term using Chart 1</p> |
| H12 | None of the conditions are met | | | <p>The histology with the numerically higher ICD-O-3 code</p> | |

Colon Multiple Primary Rules – Matrix C180-C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

- * Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
 ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|--|--|--|--|---|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMORS | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted. | Single* |
| SINGLE TUMOR | | | | | 1. Tumor not described as metastasis 2. Includes combinations of in situ and invasive | |
| M2 | Single | | | | Tumor may overlap onto or extend into adjacent/contiguous site or subsite | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | 1. Tumors not described as metastases 2. Includes combinations of in situ and invasive | |
| M3 | | Adenocarcinoma in adenomatous polyposis (familial polyposis) with one or more malignant polyps | | | Tumors may be present in multiple segments of the colon or in a single segment of the colon. | Single* |
| M4 | Sites with topography codes that are different at the second (Cxxx), third (Cxxx) or fourth (C18x) character | | | | | Multiple** |
| M5 | | | Diagnosed more than one (1) year apart | | | Multiple** |
| M6 | | | More than 60 days after diagnosis | An invasive tumor following an in situ tumor | 1: The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. 2: Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. | Multiple** |

Colon Multiple Primary Rules – Matrix C180-C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|---|--|--------|----------|--|------------|
| M7 | | A frank in situ or malignant adenocarcinoma and an in situ or malignant tumor in a polyp | | | | Single* |
| M8 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a specific histology; OR • Carcinoma, NOS (8010) and a specific carcinoma; OR • Adenocarcinoma, NOS (8140) and a specific adenocarcinoma; OR • Sarcoma, NOS (8800) and a specific sarcoma | | | | Single* |
| M9 | | Multiple in situ and/or malignant polyps | | | Includes all combinations of adenomatous, tubular, villous, and tubulovillous adenomas or polyps. | Single* |
| M10 | | Histology codes are different at the first (<u>x</u> xxx), second (xx <u>x</u> x), or third (xx <u>xx</u>) number | | | | Multiple** |
| M11 | Does not meet any of the above criteria | | | | 1: When an invasive lesion follows an in situ within 60 days, abstract as a single primary. 2: All cases covered by Rule M11 are in the same segment of the colon | Single* |

Colon Histology Coding Rules – Matrix C180 – C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---------------------|--|-----------|----------|--|---|
| SINGLE TUMOR | | | | | |
| H1 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT, PET or MRI scans <p>2: Code the specific histology when documented.</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H2 | None from primary site | | | Code the behavior /3 | The histology from metastatic site |

Colon Histology Coding Rules – Matrix C180 – C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|---|----------|---|--|
| H3 | | Intestinal type adenocarcinoma or adenocarcinoma, intestinal type | | <p>1: Intestinal type adenocarcinoma usually occurs in the stomach.</p> <p>2: When a diagnosis of intestinal adenocarcinoma is further described by a specific term such as type, continue to the next rule.</p> | 8140 (Adenocarcinoma, NOS) |
| H4 | | <p>Final diagnosis:</p> <ul style="list-style-type: none"> • Adenocarcinoma in a polyp or • Adenocarcinoma and a residual polyp or polyp architecture is recorded in other parts of the pathology report or • Adenocarcinoma and there is reference to a residual or pre-existing polyp within the medical record or • Mucinous/colloid or signet ring cell adenocarcinoma in a polyp or <p>There is documentation that the patient had a polypectomy</p> | | <p>1: It is important to know that the adenocarcinoma originated in a polyp.</p> <p>2: Code adenocarcinoma in a polyp only when the malignancy is in the residual polyp (adenoma) or references to a pre-existing polyp (adenoma) indicate that the malignancy and the polyp (adenoma) are the same lesion.</p> | 8210 (Adenocarcinoma arising in polyp), or 8261 (Adenocarcinoma in a villous adenoma), or 8263 (Adenocarcinoma in a tubulovillous adenoma) |
| H5 | | <p>Final diagnosis is:</p> <ul style="list-style-type: none"> • Mucinous/colloid (8480) or signet ring cell carcinoma (8490) or • Adenocarcinoma, NOS and microscopic description documents 50% or more of the tumor is mucinous/colloid or • Adenocarcinoma, NOS and microscopic description documents 50% or more of the tumor is signet ring cell carcinoma | | | 8480 (Mucinous/colloid adenocarcinoma) or 8490 (Signet ring cell carcinoma) |

**Colon Histology Coding Rules – Matrix
C180 – C189**

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|-------------|------------------------------------|--|----------------------|---------------------------|---|
| H6 | | Final diagnosis is adenocarcinoma and: <ul style="list-style-type: none"> • Microscopic description states less than 50% of the tumor is mucinous/colloid, or • Microscopic description states less than 50% of the tumor is signet ring cell carcinoma, or • Percentage of Mucinous/colloid or signet ring cell carcinoma is unknown | | | 8140 (Adenocarcinoma, NOS) |
| H7 | | Combination of mucinous/colloid and signet ring cell carcinoma | | | 8255 (Adenocarcinoma with mixed subtypes) |
| H8 | | Neuroendocrine carcinoma (8246) and carcinoid tumor (8240) | | | 8240 (Carcinoid tumor, NOS) |
| H9 | | Adenocarcinoma and carcinoid tumor | | | 8244 (Composite carcinoid) |
| H10 | | <u>Exactly</u> “adenocarcinoid” | | | 8245 (Adenocarcinoid) |
| H11 | | One type | | | The histology |
| H12 | | | Invasive and in situ | | The invasive histologic type |

Colon Histology Coding Rules – Matrix C180 – C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|--------------------------------------|---|----------|---|--|
| H13 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology or • Carcinoma, NOS (8010) and a more specific carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Sarcoma, NOS (8800) and a more specific sarcoma (invasive only) | | <p><i>1.</i> The specific histology for in situ tumors may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ____differentiation.</p> <p><i>2.</i> The specific histology for invasive tumors may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation.</p> | The most specific histologic term |
| H14 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Colon Histology Coding Rules – Matrix C180 – C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|--|--|-----------|----------|---|---|
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| These rules only apply to multiple tumors that are reported as a single primary | | | | | |
| H15 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT, PET or MRI scans <p>2: Code the specific histology when documented</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H16 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |

Colon Histology Coding Rules – Matrix C180 – C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|---|----------|---|--|
| H17 | | <ul style="list-style-type: none"> • Clinical history says familial polyposis and final diagnosis on pathology report from resection is adenocarcinoma in adenomatous polyps, or • > 100 polyps in resected specimen or • Number of polyps is not given but the diagnosis is familial polyposis | | | 8220 (Adenocarcinoma in adenomatous polyposis coli) |
| H18 | | Multiple in situ or malignant polyps are present, at least one of which is tubulovillous | | Use this rule only when there are multiple polyps or adenomas. Do not use this rule if there is a frank adenocarcinoma and a malignancy in a single polyp or adenoma. | 8263 (Adenocarcinoma in a tubulovillous adenoma) |
| H19 | | <ul style="list-style-type: none"> • >1 and <= 100 polyps identified in resected specimen, or • Multiple polyps (adenomas) and the number is not given and familial polyposis is not mentioned | | Use this rule only when there are multiple polyps. Do not use for a single polyp (adenoma) or for a frank malignancy and a malignancy in a single polyp (adenoma). | 8221 (adenocarcinoma in multiple adenomatous polyps) |

Colon Histology Coding Rules – Matrix C180 – C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|--|----------|---|---|
| H20 | | <ul style="list-style-type: none"> • Frank adenocarcinoma and a carcinoma in a polyp, or • In situ and invasive tumors or • Multiple invasive tumors | | <p>1: See the Colon Equivalent Terms, Definitions and Illustrations for the definition of most invasive.</p> <ul style="list-style-type: none"> • One tumor is in situ and one is invasive, code the histology from the invasive tumor. • Both/all histologies are invasive, code the histology of the most invasive tumor. <p>2: If tumors are equally invasive, go to the next rule</p> | The histology of the most invasive tumor |
| H21 | | <p>Final diagnosis:</p> <ul style="list-style-type: none"> • Adenocarcinoma and the microscopic description or surgical gross describes polyps or • Adenocarcinoma and there is reference to residual or pre-existing polyps or • Mucinous/colloid or signet ring cell adenocarcinoma in polyps or <p>There is documentation that the patient had a polypectomy</p> | | It is important to know that the adenocarcinoma originated in a polyp. | 8210 (Adenocarcinoma arising in polyp), or 8261 (Adenocarcinoma in a villous adenoma), or 8263 (Adenocarcinoma in a tubulovillous adenocarcinoma) |
| H22 | | One type | | | The histology |

Colon Histology Coding Rules – Matrix C180 – C189

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|--------------------------------------|---|----------|--|--|
| H23 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a specific histology or • Carcinoma, NOS (8010) and a specific carcinoma or • Adenocarcinoma, NOS (8140) and a specific adenocarcinoma or • Sarcoma, NOS (8800) and a specific sarcoma (invasive only) | | <p>1: The specific histology for in situ tumors may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with _____ differentiation</p> <p>2: The specific histology for invasive tumors may be identified as type, subtype, predominantly, with features of, major, or with _____ differentiation.</p> | The more specific histologic term |
| H24 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Lung Multiple Primary Rules – Matrix C340-C349

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.

** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|---|--|--------|----------|--|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMORS | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | 1: Use this rule only after all information sources have been exhausted. 2: Use this rule when only one tumor is biopsied but the patient has two or more tumors in one lung and may have one or more tumors in the contralateral lung. (See detailed explanation in Lung Equivalent Terms and Definitions) | Single* |
| SINGLE TUMOR | | | | | Tumor not described as metastasis | |
| M2 | Single | | | | The tumor may overlap onto or extend into adjacent/contiguous site or subsite. | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | Tumors not described as metastases | |
| M3 | Sites with topography codes that are different at the second (C <u>x</u> xx) and/or third (Cx <u>x</u> x) character | | | | This is a change in rules; tumors in the trachea (C33) and in the lung (C34) were a single primary in the previous rules. | Multiple** |
| M4 | | Non-small cell carcinoma (8046) and another tumor that is small cell carcinoma (8041-8045) | | | | Multiple** |
| M5 | | Adenocarcinoma with mixed subtypes (8255) and another that is bronchioloalveolar (8250-8254) | | | | Multiple** |
| M6 | Single tumor in each lung | | | | When there is a single tumor in each lung abstract as multiple primaries unless stated or proven to be metastatic. | Multiple** |

Lung Multiple Primary Rules – Matrix C340-C349

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|-------------------------------|---|---|--|--|------------|
| M7 | Multiple tumors in both lungs | Histology codes are different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number | | | | Multiple** |
| M8 | | | Diagnosed more than three (3) years apart | | | Multiple** |
| M9 | | | More than 60 days after diagnosis | An invasive tumor following an in situ tumor | <p>1: The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed.</p> <p>2: Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease.</p> | Multiple** |
| M10 | | Non-small cell carcinoma, NOS (8046) and a more specific non-small cell carcinoma type (Chart 1) | | | | Single * |
| M11 | | Histology codes are different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number | | | Adenocarcinoma in one tumor and squamous cell carcinoma in another tumor are multiple primaries. | Multiple** |

Lung Multiple Primary Rules – Matrix C340-C349

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|---|-----------|--------|----------|---|---------|
| M12 | Does not meet any of the above criteria | | | | <p>1: When an invasive tumor follows an in situ tumor within 60 days, abstract as a single primary.</p> <p>2: All cases covered by this rule are the same histology</p> <p>Rule M12 Examples The following are examples of the types of cases that use Rule M12. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary.</p> <p>Warning: Using only these case examples to determine the number of primaries can result in major errors.</p> <p>Example 1: Solitary tumor in one lung, multiple tumors in contralateral lung</p> <p>Example 2: Diffuse bilateral nodules (This is the only condition when laterality = 4)</p> <p>Example 3: An in situ and invasive tumor diagnosed within 60 days</p> <p>Example 4: Multiple tumors in the left lung metastatic from right lung</p> <p>Example 5: Multiple tumors in one lung</p> <p>Example 6: Multiple tumors in both lungs.</p> | Single* |

Lung Histology Coding Rules – Matrix C340-C349

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---------------------|--|-----------|----------------------|---|---|
| SINGLE TUMOR | | | | | |
| H1 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of cancer (histology) in the medical record • CT, PET, or MRI scans • Chest x-rays <p>2: Code the specific histology when documented.</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H2 | None from primary site | | | Code the behavior /3 | The histology from metastatic site |
| H3 | | One type | | <p>Do not code terms that do not appear in the histology description</p> <p>Example 1: Do not code squamous cell carcinoma non-keratinizing unless the words “non-keratinizing” actually appear in the diagnosis</p> <p>Example 2: Do not code bronchioalveolar non-mucinous unless the words “non-mucinous” actually appear in the diagnosis</p> | The histology |
| H4 | | | Invasive and in situ | | The invasive histologic type |

Lung Histology Coding Rules – Matrix C340-C349

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|--|----------|---|--|
| H5 | | <p>Multiple histologies all within the same branch on Chart 1.</p> <p>Examples of histologies within same branch:</p> <ul style="list-style-type: none"> • Carcinoma, NOS (8010) and a more specific carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Squamous cell carcinoma, NOS (8070) and a more specific squamous cell carcinoma or • Sarcoma, NOS (8800) and a more specific sarcoma. | | <p>The specific histology may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation. The specific histology may also be identified as follows: adenocarcinoma, clear cell or clear cell adenocarcinoma.</p> <p>Example 1: Adenocarcinoma, predominantly mucinous. Code 8480 (mucinous adenocarcinoma).</p> <p>Example 2: Non-small cell carcinoma, papillary squamous cell. Code 8052 (papillary squamous cell carcinoma).</p> | The most specific term using Chart 1 |
| H6 | | Multiple specific or a non-specific with multiple specific (Table 1) | | <p>The specific histologies may be identified as type, subtype, predominantly, with features of, major, or with differentiation</p> <p>Example 1 (multiple specific histologies): Solid and papillary adenocarcinoma. Code 8255 (adenocarcinoma with mixed subtypes).</p> <p>Example 2 (multiple specific histologies): Combined small cell and squamous cell carcinoma. Code 8045 (combined small cell carcinoma).</p> <p>Example 3 (non-specific with multiple specific histologies): Adenocarcinoma with papillary and clear cell features. Code 8255 (adenocarcinoma with mixed subtypes).</p> | The appropriate combination/mixed code (Table 1) |

Lung Histology Coding Rules – Matrix C340-C349

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--|-----------|----------|--|--|
| H7 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H8 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT, PET, or MRI scans • Chest x-rays <p>2: Code the specific histology when documented</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H9 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |
| H10 | | One type | | <p>Do not code terms that do not appear in the histology description</p> <p>Example 1: Do not code squamous cell carcinoma non-keratinizing unless the words “non-keratinizing” actually appear in the diagnosis.</p> <p>Example 2: Do not code bronchioalveolar non-mucinous unless the words “non-mucinous” actually appear in the diagnosis.</p> | The histology |

Lung Histology Coding Rules – Matrix C340-C349

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|--------------------------------------|---|----------|--|--|
| H11 | | | | <p>1: This rule should only be used when the first three digits of the histology codes are identical (This is a single primary).</p> <p>2: See the Lung Equivalent Terms, Definitions, Charts, Tables and Illustrations for the definition of most invasive.</p> <ul style="list-style-type: none"> • One tumor is in situ and one is invasive, code the histology from the invasive tumor • Both/all histologies are invasive, code the histology of the most invasive tumor. | The histology of the most invasive tumor |
| H12 | | <p>Multiple histologies all within the same branch on Chart 1. Examples of histologies within same branch:</p> <ul style="list-style-type: none"> • Carcinoma, NOS (8010) and a more specific carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Squamous cell carcinoma, NOS (8070) and a more specific squamous cell carcinoma or • Sarcoma, NOS (8800) and a more specific sarcoma. | | <p>The specific histology may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation. The specific histology may also be identified as follows: adenocarcinoma, clear cell or clear cell adenocarcinoma.</p> <p>Example 1: Adenocarcinoma, predominantly mucinous. Code 8480 (mucinous adenocarcinoma).</p> <p>Example 2: Non-small cell carcinoma, papillary squamous cell. Code 8052 (papillary squamous cell carcinoma).</p> | The most specific term using Chart 1 |
| H13 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

This page left blank

Cutaneous Melanoma Multiple Primary Rules – Matrix
C440 – C449
(Excludes melanoma of any other site)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
 ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|--|--|--------|----------|---|------------|
| UNKNOWN IF SINGLE OR MULTIPLE MELANOMAS | | | | | Melanoma(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted. | Single* |
| SINGLE MELANOMA | | | | | <i>1:</i> Melanoma not described as metastasis <i>2:</i> Includes combinations of in situ and invasive | |
| M2 | Single | | | | | Single* |
| MULTIPLE MELANOMAS Multiple melanomas may be a single primary or multiple primaries | | | | | <i>1:</i> Melanoma not described as metastases <i>2:</i> Includes combinations of in situ and invasive | |
| M3 | Topography codes are different at the second (C <u>x</u> xx), third (Cxx <u>x</u>) or fourth (Cxxx) character | | | | | Multiple** |
| M4 | Different laterality | | | | A midline melanoma is a different laterality than right or left. <i>Example 1:</i> A melanoma on the right side of the chest and a melanoma at midline on the chest are different laterality, multiple primaries. <i>Example 2:</i> A melanoma on the right side of the chest and a melanoma on the left side of the chest are multiple primaries. | Multiple** |
| M5 | | Histology codes are different at the first (<u>x</u> xxx), second (xx <u>x</u>), or third (xxx <u>x</u>) number | | | | Multiple** |

Cutaneous Melanoma Multiple Primary Rules – Matrix
C440 – C449
(Excludes melanoma of any other site)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|-------------|---|------------------|-----------------------------------|--|---|----------------|
| M6 | | | More than 60 days after diagnosis | An invasive melanoma following an in situ melanoma | 1: The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. 2: Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. | Multiple** |
| M7 | | | Diagnosed more than 60 days apart | | | Multiple** |
| M8 | Does not meet any of the above criteria | | | | 1: Use the data item “Multiplicity Counter” to record the number of melanomas abstracted as a single primary. 2: When an invasive melanoma follows an in situ melanoma within 60 days, abstract as a single primary. 3: All cases covered by this rule are the same site and histology. Rule M8 Examples The following are examples of the types of cases that use Rule M8. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary. Warning: Using only these case examples to determine the number of primaries can result in major errors. Example 1: Solitary melanoma on the left back and another solitary melanoma on the left chest Example 2: Solitary melanoma on the right thigh and another solitary melanoma on the right ankle | Single* |

Cutaneous Melanoma Histology Coding Rules – Matrix
C440-C449
(Excludes melanoma of all other sites)

| Rule | Melanoma Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--|--|----------------------|--|---|
| SINGLE MELANOMA OR MULTIPLE MELANOMAS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H1 | No pathology/cytology specimen or the pathology/cytology report is not available | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of melanoma in the medical record • PET scan 2: Code the specific histology when documented. | The histology documented by the physician |
| H2 | None from primary site | | | Code the behavior /3 | The histology from metastatic site |
| H3 | | One type | | | The histology |
| H4 | | | Invasive and in situ | | The invasive histologic type |
| H5 | | Regressing melanoma and a histologic type | | Example: Nodular melanoma with features of regression. Code 8721 (Nodular melanoma). | The histologic type |
| H6 | | Regressing melanoma | | Example: Malignant melanoma with features of regression. Code 8723. | 8723 (Malignant melanoma, regressing) |
| H7 | | Lentigo maligna melanoma and a histologic type | | | The histologic type |
| H8 | | Lentigo maligna melanoma | | | 8742 (Lentigo maligna melanoma) |
| H9 | | Melanoma, NOS (8720) with a single specific type | | 1. The specific type for in situ lesions may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ____differentiation. 2. The specific type for invasive lesions may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation. | The most specific histologic term |

Cutaneous Melanoma Histology Coding Rules – Matrix
C440-C449
(Excludes melanoma of all other sites)

| Rule | Melanoma Specimen | Histology | Behavior | Notes and Examples | Code |
|-------------|--------------------------|--------------------------------------|-----------------|---------------------------|--|
| H10 | | None of the above conditions are met | | | The histology with the numerically higher ICD-O-3 code |

Breast Multiple Primary Rules – Matrix C500 – C509

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.

** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|---|------------------------|--|--|---|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMORS | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted. | Single* |
| SINGLE TUMOR | | | | | <i>1:</i> Tumor not described as metastasis <i>2:</i> Includes combinations of in situ and invasive | |
| M2 | One or both breasts | Inflammatory carcinoma | | | | Single* |
| M3 | Single | | | | The tumor may overlap onto or extend into adjacent/contiguous site or subsite | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | <i>1:</i> Tumors not described as metastases <i>2:</i> Includes combinations of in situ and invasive | |
| M4 | Topography codes different at the second (C _{xxx}) and/or third (C _{xxx}) character | | | | | Multiple** |
| M5 | | | Diagnosed more than five (5) years apart | | | Multiple** |
| M6 | One or both breasts | Inflammatory carcinoma | | | | Single* |
| M7 | Both breasts | | | | Lobular carcinoma in both breasts (“mirror image”) is a multiple primary | Multiple** |
| M8 | | | More than 60 days after diagnosis | An invasive tumor following an in situ tumor | <i>1:</i> The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. <i>2:</i> Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. | Multiple** |

Breast Multiple Primary Rules – Matrix C500 – C509

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|---|---|--------|----------|--|------------|
| M9 | | Intraductal and/or duct and Paget Disease | | | Use Table 1 and Table 2 to identify intraductal and duct carcinomas | Single* |
| M10 | | Lobular (8520) and intraductal or duct | | | Use Table 1 and Table 2 to identify intraductal and duct carcinomas | Single* |
| M11 | | Multiple intraductal and/or duct carcinomas | | | Use Table 1 and Table 2 to identify intraductal and duct carcinomas | Single* |
| M12 | | Histology codes are different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number | | | | Multiple** |
| M13 | Does not meet any of the above criteria | | | | <p>1: When an invasive tumor follows an in situ tumor within 60 days, abstract as a single primary.</p> <p>2: All cases covered by Rule M13 have the same first 3 numbers in ICD-O-3 histology code</p> <p>Rule M13 Examples</p> <p>The following are examples of the types of cases that use Rule M13. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary.</p> <p>Warning: <i>Using only these case examples to determine the number of primaries can result in major errors.</i></p> <p>Example 1: Invasive duct and intraductal carcinoma in the same breast</p> <p>Example 2: Multi-centric lobular carcinoma, left breast</p> | Single* |

**Breast Histology Coding Rules – Matrix
C500-C509**

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|--|--|--|----------|---|--|
| SINGLE TUMOR: IN SITU ONLY (Single tumor; all parts are in situ) | | | | | |
| H1 | The pathology/cytology report is not available | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> Documentation in the medical record that refers to pathologic or cytologic findings From clinician reference to type of cancer (histology) in the medical record 2: Code the specific histology when documented. | The histology documented by the physician |
| H2 | | One type | | | The histology |
| H3 | | <ul style="list-style-type: none"> Carcinoma in situ, NOS (8010) and a specific carcinoma in situ or Adenocarcinoma in situ, NOS (8140) and a specific adenocarcinoma in situ or Intraductal carcinoma, NOS (8500) and a specific intraductal carcinoma (Table 1) | | The specific histology may be identified as type, subtype, predominantly, with features of, major, or with ___ differentiation, architecture or pattern. The terms architecture and pattern are subtypes only for in situ cancer. | The more specific histologic term |
| H4 | | Non-infiltrating comedocarcinoma and any other intraductal carcinoma (Table 1) | | Example: Pathology report reads intraductal carcinoma with comedo and solid features. Code 8501/2 (comedocarcinoma). | 8501/2 (comedocarcinoma, non-infiltrating) |
| H5 | | In situ lobular (8520) and intraductal carcinoma (Table 1) | | | 8522/2 (intraductal carcinoma and lobular carcinoma in situ) (Table 3). |

**Breast Histology Coding Rules – Matrix
C500-C509**

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|-----------|-----------------------------|---|----------|--|--|
| H6 | | <ul style="list-style-type: none"> • Combination of intraductal carcinoma and two or more specific and two or more specific intraductal types OR • Two or more specific intraductal carcinomas | | <p><i>1:</i> Use Table 1 to identify the histologies <i>2:</i> Change the behavior to 2 (in situ) in accordance with the ICD-O-3 matrix principle (ICD-O-3 Rule F.)</p> | 8523/2 (intraductal carcinoma mixed with other types of in situ carcinoma) (Table 3) . |
| H7 | | In situ lobular (8520) and any in situ carcinoma other than intraductal carcinoma (Table 1) | | Change the behavior to 2 (in situ) in accordance with the ICD-O-3 matrix principle (ICD-O-3 Rule F.) | 8524/2 (in situ lobular mixed with other types of in situ carcinoma) (Table 3) . |
| H8 | | Combination of in situ/non-invasive histologies that does not include either intraductal carcinoma (Table 1) or in situ lobular (8520) | | Change the behavior to 2 (in situ) in accordance with the ICD-O-3 matrix principle (ICD-O-3 Rule F.) | 8255/2 (adenocarcinoma in situ with mixed subtypes) (Table 3) . |

**Breast Histology Coding Rules – Matrix
C500-C509**

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|--|--|------------------|----------------------|--|---|
| SINGLE TUMOR: INVASIVE AND IN SITU (Single tumor; in situ and invasive components) | | | | | |
| H9 | | | Invasive and in situ | <p>1. Ignore the in situ terms.</p> <p>2. This is a change from the previous histology coding rules and is different from ICD-O-3 rules. This change was made in collaboration with the ICD-O-3 editors. The consensus was that coding the invasive component of the tumor better explains the likely disease course and survival category. Using these rules, combinations of invasive duct and in situ lobular are coded to invasive duct (8500/3) rather than the combination code for duct and lobular carcinoma (8522/3).</p> | The invasive histology |
| SINGLE TUMOR: INVASIVE ONLY (Single tumor; all parts are invasive) | | | | | |
| H10 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • Mammogram • PET scan • Ultrasound <p>2: Code the specific histology when documented</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H11 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |

**Breast Histology Coding Rules – Matrix
C500-C509**

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------------|-----------------------------|---|----------|---|--|
| H12 | | <ul style="list-style-type: none"> • Carcinoma, NOS (8010) and a more specific carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Duct carcinoma, NOS (8500) and a more specific duct carcinoma (8022, 8035, 8501-8508) or • Sarcoma, NOS (8800) and a more specific sarcoma | | The specific histology may be identified as type, subtype, predominantly, with features of, major, or with ___differentiation. The terms architecture and pattern are subtypes only for in situ cancer. | The most specific histologic term |
| H13 | | Final diagnosis of the pathology report specifically states inflammatory carcinoma | | Record dermal lymphatic invasion in Collaborative Staging | 8530 (inflammatory carcinoma) |
| H14 | | One type | | | The histology |
| H15 | | Two or more specific duct carcinomas | | Use Table 2 to identify duct carcinomas | The histology with the numerically higher ICD-O-3 code |
| H16 | | Combination of lobular (8520) and duct carcinoma | | Use Table 2 to identify duct carcinomas | 8522 (duct and lobular) (Table 3). |
| H17 | | Combination of duct and any other carcinoma | | <i>1:</i> Use Table 2 to identify duct carcinomas <i>2:</i> Other carcinomas exclude lobular and any duct carcinoma listed on Table 1 or Table 2. | 8523 (duct mixed with other types of carcinoma) (Table 3). |

**Breast Histology Coding Rules – Matrix
C500-C509**

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--|--|-----------------|--|--|
| H18 | | Lobular (8520) and any other carcinoma | | Other carcinomas exclude lobular and any duct carcinoma listed on Table 1 or Table 2 | 8524 (lobular mixed with other types of carcinoma) (Table 3) . |
| H19 | | Multiple histologies that do not include duct or lobular (8520) | | Use Table 2 to identify duct carcinomas | 8255 (adenocarcinoma with mixed subtypes) (Table 3) . |
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H20 | No pathology/cytology specimen or the pathology/cytology report is not available | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • Mammogram • PET scan • Ultrasound 2: Code the specific histology when documented 3: Code the histology to cancer/malignant neoplasm, NOS (8000) or carcinoma, NOS (8010) as stated by the physician when nothing more specific is documented | The histology documented by the physician |
| H21 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |
| H22 | | Final diagnosis of the pathology report specifically states inflammatory carcinoma | | Note: Record dermal lymphatic invasion in Collaborative Staging | 8530 (inflammatory carcinoma) |
| H23 | | One type | | | The histology |

Breast Histology Coding Rules – Matrix C500-C509

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|---|----------------------|---|--|
| H24 | | Pathology report specifically states Paget disease is in situ and the underlying tumor is intraductal carcinoma (Table 1) | | Change the behavior to 2 (in situ) in accordance with the ICD-O-3 matrix principle (ICD-O-3 Rule F.) | Code 8543/2 (in situ Paget disease and intraductal carcinoma) (Table 3). |
| H25 | | Paget disease and intraductal carcinoma | | <ol style="list-style-type: none"> 1. ICD-O-3 classifies all mammary Paget disease as a malignant process with a malignant behavior (/3). 2. Includes both invasive Paget disease and Paget disease with behavior not stated. 3: Use Table 1 to identify intraductal carcinomas | 8543/3 (Paget disease and intraductal carcinoma) (Table 3). |
| H26 | | Paget disease and invasive duct carcinoma | | <ol style="list-style-type: none"> 1. ICD-O-3 classifies all mammary Paget disease as a malignant process with a malignant behavior (/3). 2. Includes both invasive Paget disease and Paget disease with behavior not stated. 3: Use Table 2 to identify duct carcinomas | Code 8541/3 (Paget disease and infiltrating duct carcinoma) (Table 3). |
| H27 | | | Invasive and in situ | <ol style="list-style-type: none"> 1. Ignore the in situ terms. 2. This is a change from the previous histology coding rules and is different from ICD-O-3 rules. This change was made in collaboration with the ICD-O-3 editors. The consensus was that coding the invasive component of the tumor better explains the likely disease course and survival category. Using these rules, combinations of invasive lobular and in situ duct carcinoma are coded to invasive lobular (8520/3) rather than the combination code for duct and lobular carcinoma (8522/3) | The invasive histology |

**Breast Histology Coding Rules – Matrix
C500-C509**

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|-------------|------------------------------------|-----------------------------------|-----------------|---|--|
| H28 | | Lobular (8520) and duct carcinoma | | Use Table 2 to identify duct carcinomas | 8522 (duct and lobular) (Table 3) . |
| H29 | None of the conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Breast Histology Coding Rules – Matrix
C500-C509
(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

This page left blank

Kidney Multiple Primary Rules – Matrix C649

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.

** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|---|--------------|---|----------|--|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMORS | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted. | Single* |
| SINGLE TUMOR | | | | | <i>1.</i> Tumor not described as metastasis <i>2:</i> Includes combinations of in situ and invasive | |
| M2 | Single | | | | Tumor may overlap onto or extend into adjacent/contiguous site or subsite | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | <i>1.</i> Tumors not described as metastases <i>2:</i> Includes combinations of in situ and invasive | |
| M3 | | Wilms tumors | | | | Single* |
| M4 | Tumors with topography codes that differ at the second (C <u>x</u> xx) and/or third (Cx <u>xx</u>) character | | | | | Multiple** |
| M5 | Tumors in both right and left kidneys | | | | Abstract as a single primary when the tumors in one kidney are documented to be metastatic from the other kidney | Multiple** |
| M6 | | | Diagnosed more than three (3) years apart | | | Multiple** |

Kidney Multiple Primary Rules – Matrix C649

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|------|--|-----------------------------------|--|---|------------|
| M7 | | | More than 60 days after diagnosis | An invasive tumor following an in situ tumor | <i>1:</i> The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. <i>2:</i> Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. | Multiple** |
| M8 | | A renal cell type in one tumor and a different specific renal cell type in another (Table 1) | | | | Multiple** |
| M9 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and another is a specific histology or • Carcinoma, NOS (8010) and another is a specific carcinoma or • Adenocarcinoma, NOS (8140) and another is a specific adenocarcinoma or • Renal cell carcinoma, NOS (8312) and the other is a single renal cell type (Table 1) | | | <i>1:</i> The specific histology for in situ tumors may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ____differentiation <i>2:</i> The specific histology for invasive tumors may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation. | Single* |
| M10 | | Histology codes are different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number | | | | Multiple** |

Kidney Multiple Primary Rules – Matrix C649

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|---|-----------|--------|----------|--|---------|
| M11 | Does not meet any of the above criteria | | | | <p>When an invasive tumor follows an in situ tumor within 60 days, abstract as a single primary.</p> <p>Rule M11 Examples The following are examples of the types of cases that use Rule M11. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary.</p> <p>Warning: <i>Using only these case examples to determine the number of primaries can result in major errors.</i></p> <p>Example 1: Multiple tumors in one kidney with the same histology Example 2: An in situ and invasive tumor diagnosed within 60 days</p> | Single* |

Kidney Histology Coding Rules – Matrix C649

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---------------------|---|--|----------------------|---|---|
| SINGLE TUMOR | | | | | |
| H1 | None or the pathology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT or MRI scans <p>2: Code the specific histology when documented.</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H2 | None from primary site | | | Code the behavior /3 | The histology from metastatic site |
| H3 | | One type | | | The histology |
| H4 | | | Invasive and in situ | | The invasive histologic type |
| H5 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology or • Carcinoma, NOS (8010) and a more specific carcinoma or Adenocarcinoma, NOS (8041) and one specific adenocarcinoma type or • Renal cell carcinoma (8312) and one specific renal cell type. | | <p>1: Use Table 1 to identify specific renal cell types.</p> <p>2: The specific histology for in situ tumors may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ____ differentiation</p> <p>3: The specific histology for invasive tumors may be identified as type, subtype, predominantly, with features of, major, or with ____ differentiation.</p> | The specific type |

Kidney Histology Coding Rules – Matrix C649

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--|---|----------|--|--|
| H6 | | Two or more specific types of renal cell carcinoma. | | Use Table 1 to identify specific renal cell types <i>Example:</i> Renal cell carcinoma, papillary and clear cell types. Assign code 8255. | 8255 (Adenocarcinoma with mixed subtypes) |
| H7 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H8 | No pathology/cytology specimen or the pathology/cytology report is not available | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT or MRI scans 2: Code the specific histology when documented 3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented | The histology documented by the physician |
| H9 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |
| H10 | | One type | | | The histology |

Kidney Histology Coding Rules – Matrix C649

(Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|--------------------------------------|--|----------|--|--|
| H11 | | | | <p><i>1:</i> This rule should only be used when the first three digits of the histology codes are identical (This is a single primary).</p> <p><i>2:</i> See the Kidney Equivalent Terms, Definitions, Tables and Illustrations for the definition of most invasive.</p> <ul style="list-style-type: none"> • One tumor is in situ and one is invasive, code the histology from the invasive tumor • Both/all histologies are invasive, code the histology of the most invasive tumor. | The histology of the most invasive tumor |
| H12 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology or • Carcinoma, NOS (8010) and a more specific carcinoma or • Adenocarcinoma, NOS (8140) and one specific adenocarcinoma type or • Renal cell carcinoma (8312) and one specific renal cell type | | <p><i>1:</i> Use Table 1 to identify specific renal cell types.</p> <p><i>2:</i> The specific histology for in situ tumors may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ____differentiation</p> <p><i>3:</i> The specific histology for invasive tumors may be identified as type, subtype, predominantly, with features of, major, or with ____differentiation.</p> | The specific type |
| H13 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Renal Pelvis, Ureter, Bladder, and Other Urinary Multiple Primary Rules – Matrix
C659, C669, C670-C679, C680-C689
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
 ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|---|-----------|-----------------------------------|----------------------------------|---|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMORS | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted. | Single* |
| SINGLE TUMOR | | | | | 1: Tumor not described as metastasis 2: Includes combinations of in situ and invasive | |
| M2 | Single | | | | The tumor may overlap onto or extend into adjacent/contiguous site or subsite | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single or multiple primaries | | | | | 1: Tumors not described as metastases 2: Includes combinations of in situ and invasive | |
| M3 | When no other urinary sites are involved, tumor(s) in the right renal pelvis and tumor(s) the left renal pelvis | | | | Use this rule and abstract as a multiple primary unless documented to be metastatic. | Multiple** |
| M4 | When no other urinary sites are involved, tumor(s) in the right ureter and tumor(s) in the left ureter | | | | Use this rule and abstract as a multiple primary unless documented to be metastatic. | Multiple** |
| M5 | | | More than 60 days after diagnosis | An invasive following an in situ | 1: The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. 2: Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. | Multiple** |

Renal Pelvis, Ureter, Bladder, and Other Urinary Multiple Primary Rules – Matrix
C659, C669, C670-C679, C680-C689

(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|-------------|--|--|---------------------------------|-----------------|---|----------------|
| M6 | Bladder | Any combination of: <ul style="list-style-type: none"> • Papillary carcinoma (8050) or • Transitional cell carcinoma (8120-8124) or • Papillary transitional cell carcinoma (8130-8131) | | | | Single* |
| M7 | | | More than three (3) years apart | | | Multiple** |
| M8 | Two or more of the following sites <ul style="list-style-type: none"> • Renal pelvis (C659) • Ureter(C669) • Bladder (C670-C679) • Urethra /prostatic urethra (C680) | Urothelial tumors (See Table 1)* | | | | Single* |
| M9 | | Tumors with histology codes different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number | | | | Multiple** |
| M10 | Tumors with topography codes different at the second (C <u>x</u> xx) and/or third (Cx <u>x</u> x) character | | | | | Multiple** |
| M11 | Does not meet any of the above criteria | | | | When an invasive tumor follows an in situ tumor within 60 days, abstract as a single primary. | Single* |

**Renal Pelvis, Ureter, Bladder, and Other Urinary Histology Coding Rules – Matrix
C659, C669, C670-C679, C680-C689
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)**

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---------------------|--|---|-----------------|---|--|
| SINGLE TUMOR | | | | | |
| H1 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <p><i>1:</i> Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of cancer (histology) in the medical record • CT or MRI scans <p><i>2:</i> Code the specific histology when documented.</p> <p><i>3:</i> Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H2 | None from primary site | | | Code the behavior /3 | The histology from metastatic site |
| H3 | | <ul style="list-style-type: none"> • Pure transitional carcinoma or • Flat (non—papillary) transitional cell carcinoma or • Transition cell carcinoma with squamous differentiation or • Transitional cell carcinoma with glandular differentiation or • Transitional cell carcinoma with trophoblastic differentiation or • Nested transitional cell carcinoma or • Microcystic transitional cell carcinoma | | Flat transitional cell carcinoma is a more important prognostic indicator than papillary, and is likely to be treated more aggressively. | 8120 (transitional cell/urothelial carcinoma) (Table 1 – Code 8120) |

Renal Pelvis, Ureter, Bladder, and Other Urinary Histology Coding Rules – Matrix
C659, C669, C670-C679, C680-C689
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------|--------------------------------------|---|----------------------|---|---|
| H4 | | <ul style="list-style-type: none"> • Papillary carcinoma or • Papillary transitional carcinoma or • Papillary carcinoma and transitional cell carcinoma | | | 8130 (papillary transitional cell carcinoma) (Table 1 – Code 8130) |
| H5 | | One type | | Only code squamous cell carcinoma (8070) when there are no other histologies present (pure squamous cell carcinoma) | The histology |
| H6 | | | Invasive and in situ | | The invasive histologic type |
| H7 | | <p>Examples</p> <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology; or • Carcinoma, NOS (8010) and a more specific carcinoma; or • Sarcoma, NOS (8800) and a more specific sarcoma (invasive only) | | <p><i>1:</i> The specific histology for in situ lesions may be identified as pattern, architecture, type, subtype, predominantly, with features of, or with _____ differentiation.</p> <p><i>2:</i> The specific histology for invasive lesions may be identified as type, subtype, predominantly, with features of, or with _____ differentiation.</p> | The most specific histologic term |
| H8 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Renal Pelvis, Ureter, Bladder, and Other Urinary Histology Coding Rules – Matrix
C659, C669, C670-C679, C680-C689
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--|---|----------|--|--|
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H9 | None or the pathology/cytology report is not available | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • From reports or notes in the medical record that document or reference pathologic or cytologic findings • From clinician reference to type of cancer in the medical record • From CT or MRI scans <p>2: Code the specific histology when documented</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H10 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |
| H11 | | <ul style="list-style-type: none"> • Pure transitional carcinoma or • Flat (non—papillary) transitional cell carcinoma or • Transition cell carcinoma with squamous differentiation or • Transitional cell carcinoma with glandular differentiation or • Transitional cell carcinoma with trophoblastic differentiation or • Nested transitional cell carcinoma or • Microcystic transitional cell carcinoma | | Flat transitional cell carcinoma is a more important prognostic indicator than papillary, and is likely to be treated more aggressively. | 8120 (transitional cell/urothelial carcinoma) (Table 1 – Code 8120) |

Renal Pelvis, Ureter, Bladder, and Other Urinary Histology Coding Rules – Matrix
C659, C669, C670-C679, C680-C689
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|------------|--------------------------------------|--|----------|---|---|
| H12 | | <ul style="list-style-type: none"> • Papillary carcinoma or • Papillary transitional carcinoma or • Papillary carcinoma and transitional cell carcinoma | | | 8130 (papillary transitional cell carcinoma) (Table 1 – Code 8130) |
| H13 | | One type | | Only code squamous cell carcinoma (8070) when there are no other histologies present (pure squamous cell carcinoma). | The histology |
| H14 | | | | <p><i>1:</i> This rule should only be used when the first three digits of the histology codes are identical (This is a single primary).</p> <p><i>2:</i> See the Renal Pelvis, Ureter, Bladder and Other Urinary Equivalent Terms, Definitions, Tables and Illustrations for the definition of most invasive.</p> <ul style="list-style-type: none"> • One tumor is in situ and one is invasive, code the histology from the invasive tumor • Both/all histologies are invasive, code the histology of the most invasive tumor. | The histology of the most invasive tumor |
| H15 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Benign and Borderline Intracranial and CNS Tumors
Multiple Primary Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753

Note: Malignant intracranial and CNS tumors have a separate set of rules.

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.

** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Laterality | Behavior | Notes/Examples | Primary |
|---|--|---|--|---|---|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMOR | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted | Single* |
| SINGLE TUMOR | | | | | Tumor not described as metastasis | |
| M2 | Single | | | | The tumor may overlap onto or extend into adjacent/contiguous site or subsite | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | Tumors not described as metastases | |
| M3 | Brain | | | Invasive (/3) and either a benign (/0) or uncertain / borderline (/1) | | Multiple** |
| M4 | Topography codes different at the second (C \underline{x} xx) and/or third (Cxx \underline{x}) character,), or fourth (Cxx \underline{x}) are multiple primaries. | | | | | Multiple** |
| M5 | | | Both sides (left and right) of a paired site (Table 1) | | | Multiple** |
| M6 | | Atypical choroid plexus papilloma (9390/1) following Choroid plexus papilloma, NOS (9390/0) | | | Do not code progression of disease as multiple primaries | Single* |

Benign and Borderline Intracranial and CNS Tumors
Multiple Primary Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753

| Rule | Site | Histology | Laterality | Behavior | Notes/Examples | Primary |
|-------------|-------------|--|-------------------|-----------------|--|----------------|
| M7 | | Neurofibromatosis, NOS (9540/1) Following Neurofibroma, NOS (9540/0) | | | Do not code progression of disease as multiple primaries | Single* |
| M8 | | Multiple types on the same branch in Chart 1 | | | | Single* |
| M9 | | Multiple types on different branches in Chart 1 | | | | Multiple** |
| M10 | | Multiple types, at least one not listed in Chart 1 | | | | Multiple** |
| M11 | | Codes are different at the first (<u>x</u> xxx), second (x <u>x</u> xx) or third (xx <u>x</u> x) number | | | Use this rule when none of the histology codes are listed in Chart 1 | Multiple** |

Benign and Borderline Intracranial and CNS Tumors
Multiple Primary Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753

| Rule | Site | Histology | Laterality | Behavior | Notes/Examples | Primary |
|-------------|---|------------------|-------------------|-----------------|---|----------------|
| M12 | Does not meet any of the above criteria | | | | <p>Timing is not used to determine multiple primaries for benign and borderline intracranial and CNS tumors.</p> <p>Examples: The following are examples of cases that use Rule M12. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary.</p> <p>Warning: <i>Using only these case examples to determine the number of primaries can result in major errors.</i></p> <p>Example 1: Tumors in the same site with the same histology (Chart 1) and the same laterality as the original tumor are a single primary</p> <p>Example 2: Tumors in the same site with the same histology (Chart 1) and it is unknown if laterality is the same as the original tumor are a single primary.</p> <p>Example 3: Tumors in the same site and same laterality with histology codes not listed in Chart 1 that have the same first three numbers are a single primary.</p> | Single* |

This page left blank

Benign and Borderline Intracranial and CNS Tumors
Histology Coding Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753

Note: Malignant intracranial and CNS tumors have a separate set of rules.

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--------------------------------------|---|----------|--|--|
| SINGLE TUMOR | | | | | |
| H1 | No specimen or report available | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of tumor (histology) in the medical record • PET, CT or MRI scans 2: Code the specific histology when documented 3: Code the histology to 8000 (neoplasm, NOS) as stated by the physician when nothing more specific is documented | Histology documented by the physician |
| H2 | | One type | | | The histology |
| H3 | | Multiple, all in the same branch on Chart 1 | | | The more specific histology |
| H4 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H5 | No specimen or report available | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of tumor (histology) in the medical record • PET, CT or MRI scans 2: Code the specific histology when documented 3: Code the histology to 8000 (neoplasm, NOS) as stated by the physician when nothing more specific is documented | Histology documented by the physician |

Benign and Borderline Intracranial and CNS Tumors
Histology Coding Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|-------------|---|-------------------------|---|---------------------------|--|
| H6 | Multiple meningiomas | Uncertain behavior (/1) | <p><i>1:</i> This is a rare condition that is usually associated with neurofibromatosis type 2 and other genetic disorders</p> <p><i>2:</i> Use this code only for meningiomas with uncertain behavior; do not use this code for multiple benign or malignant meningiomas</p> | 9530/1 | |
| H7 | One type | | | | The histology |
| H8 | Original diagnosis | | Do not change the histology code when a later tumor(s) shows progression of disease | | The histology from the original diagnosis. |
| H9 | Multiple, all in the same branch on Chart 1 | | | | The more specific histology |
| H10 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Malignant Meninges, Brain, Spinal Cord, Cranial Nerves, Pituitary gland, Craniopharyngeal duct and Pineal gland
Multiple Primary Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753
(Excludes lymphoma and leukemia – M9590-9989 and Kaposi sarcoma M9140)

Note: Benign and borderline intracranial and CNS tumors have a separate set of rules.

- * Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
- ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|---|--|--------|--|---|------------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMOR | | | | | Tumor(s) not described as metastasis | |
| M1 | Brain | | | Invasive (/3) and either a benign (/0) or uncertain/borderline (1) tumor | | Multiple** |
| M2 | | | | | Use this rule only after all information sources have been exhausted. | Single* |
| SINGLE TUMOR | | | | | Tumor not described as metastasis | |
| M3 | Single | | | | The tumor may overlap onto or extend into adjacent/contiguous site or subsite | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | Tumors not described as metastases | |
| M4 | Brain | | | Invasive (/3) and either a benign (/0) or uncertain/borderline (1) tumor | | Multiple** |
| M5 | Tumors with topography codes different at the second (Cxxx) and/or third (Cxxx) character | | | | | Multiple** |
| M6 | | Glioblastoma or glioblastoma multiforme (9440) following a glial tumor (See Chart 1) | | | | Single* |

Malignant Meninges, Brain, Spinal Cord, Cranial Nerves, Pituitary gland, Craniopharyngeal duct and Pineal gland

Multiple Primary Rules – Matrix

C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753

(Excludes lymphoma and leukemia – M9590-9989 and Kaposi sarcoma M9140)

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|-------------|---|--|---------------|-----------------|--|----------------|
| M7 | | Tumors with histology codes on the same branch in Chart 1 or Chart 2 | | | Recurrence, progression or any reappearance of histologies on the same branch in Chart 1 or Chart 2 is always the same disease process. <i>Example:</i> Patient has astrocytoma. Ten years later the patient is diagnosed with glioblastoma multiforme. This is a progression or recurrence of the earlier astrocytoma. | Single* |
| M8 | | Tumors with histology codes on different branches in Chart 1 or Chart 2 | | | | Multiple** |
| M9 | | Tumors with histology codes different at the first (xxxx), second (xxxx), or third (xxxx) number | | | | Multiple** |
| M10 | Does not meet any of the above criteria | | | | <i>I:</i> Neither timing nor laterality is used to determine multiple primaries for malignant intracranial and CNS tumors. <i>Example:</i> The patient is treated for an anaplastic astrocytoma (9401) in the right parietal lobe. Three months later the patient is diagnosed with a separate anaplastic astrocytoma in the left parietal lobe. This is one primary because laterality is not used to determine multiple primary status. <i>2:</i> Multi-centric brain tumors which involve different lobes of the brain that do not meet any of the above criteria are the same disease process. | Single* |

Malignant Meninges, Brain, Spinal Cord, Cranial Nerves, Pituitary gland, Craniopharyngeal duct and Pineal gland
Histology Coding Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753
(Excludes lymphoma and leukemia – M9590-9989 and Kaposi sarcoma M9140)

Note: Benign and borderline intracranial and CNS tumors have a separate set of rules.

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---------------------|--|---|-----------------|--|--|
| SINGLE TUMOR | | | | | |
| H1 | No pathology/cytology specimen or the pathology/cytology report is not available | | | <i>1:</i> Priority for using documents to code the histology <ul style="list-style-type: none"> Documentation in the medical record that refers to pathologic or cytologic findings Physician's reference to type of cancer (histology) in the medical record CT or MRI scans <i>2:</i> Code the specific histology when documented. <i>3:</i> Code the histology to 8000 (cancer/malignant neoplasm, NOS) as stated by the physician when nothing more specific is documented | The histology documented by the physician |
| H2 | None from primary site | | | Code the behavior /3 | The histology from metastatic site |
| H3 | | At least two of the following cells and/or differentiation are present: <ul style="list-style-type: none"> Astrocytoma Oligodendroglioma Ependymal | | | Code 9382/3 (mixed glioma) |
| H4 | | One type | | | The histology |
| H5 | | Diagnosis includes a non-specific term and a specific term or type on the same branch in Chart 1 or Chart 2 | | | The specific type |
| H6 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Malignant Meninges, Brain, Spinal Cord, Cranial Nerves, Pituitary gland, Craniopharyngeal duct and Pineal gland
Histology Coding Rules – Matrix
C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753
(Excludes lymphoma and leukemia – M9590-9989 and Kaposi sarcoma M9140)

| Rule | Pathology/Cytology Specimen | Histology | Behavior | Notes and Examples | Code |
|---|--|---|----------|---|--|
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | |
| H7 | No pathology/cytology specimen or the pathology/cytology report is not available | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT or MRI scans 2: Code the specific histology when documented 3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) as stated by the physician when nothing more specific is documented | The histology documented by the physician |
| H8 | None from primary site | | | Code the behavior /3 | The histology from a metastatic site |
| H9 | | One type | | | The histology |
| H10 | | Diagnosis includes a non-specific term and a specific term or type on the same branch in Chart 1 or Chart 2 | | | The specific type |
| H11 | None of the above conditions are met | | | | The histology with the numerically higher ICD-O-3 code |

Other Sites Multiple Primary Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
 ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|---|-------------------------|--------------------------|----------------|----------|---|---------|
| UNKNOWN IF SINGLE OR MULTIPLE TUMORS | | | | | Tumor(s) not described as metastasis | |
| M1 | | | | | Use this rule only after all information sources have been exhausted. | Single* |
| SINGLE TUMOR | | | | | 1: Tumor not described as metastasis 2: Includes combinations of in situ and invasive | |
| M2 | Single | | | | The tumor may overlap onto or extend into adjacent/contiguous site or subsite. | Single* |
| MULTIPLE TUMORS Multiple tumors may be a single primary or multiple primaries | | | | | 1: Tumors not described as metastases 2: Includes combinations of in situ and invasive | |
| M3 | Prostate | Adenocarcinoma | | | 1: Report only one adenocarcinoma of the prostate per patient per lifetime. 2: 95% of prostate malignancies are the common (acinar) adenocarcinoma histology (8140). See Equivalent Terms, Definitions and Tables for more information 3: If patient has a previous acinar adenocarcinoma of the prostate in the database and is diagnosed with adenocarcinoma in 2007 it is a single primary. | Single* |
| M4 | Unilateral or bilateral | Retinoblastoma | | | | Single* |
| M5 | Any site or sites | Kaposi sarcoma | | | | Single* |
| M6 | Thyroid | Follicular and papillary | Within 60 days | | | Single* |

Other Sites MP

Other Sites Multiple Primary Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|---|--|--|----------|--|------------|
| M7 | Bilateral ovary | Epithelial tumors (8000-8799) | Within 60 days of diagnosis | | | Single* |
| M8 | Both sides of a paired site (Table 1) | | | | Table 1 – Paired Organs and Sites with Laterality | Multiple** |
| M9 | | Adenocarcinoma in adenomatous polyposis coli (familial polyposis) with one or more in situ or malignant polyps | | | Tumors may be present in a single or multiple segments of the colon, rectosigmoid, rectum. | Single* |
| M10 | | | Diagnosed more than one (1) year apart | | | Multiple** |
| M11 | Topography codes that are different at the second (C <u>x</u> xx) and/or third (Cx <u>xx</u>) character | | | | <i>Example 1:</i> A tumor in the penis C <u>6</u> 09 and a tumor in the rectum C2 <u>0</u> 9 have different second characters in their ICD-O-3 topography codes, so they are multiple primaries. <i>Example 2:</i> A tumor in the cervix C5 <u>3</u> 9 and a tumor in the vulva C <u>5</u> 19 have different third characters in their ICD-O-3 topography codes, so they are multiple primaries | Multiple** |
| M12 | Topography codes that differ only at the fourth (Cxx <u>x</u>) character in any one of the following primary sites: <ul style="list-style-type: none"> • Anus and anal canal C21_) • Bones, joints and articular cartilage (C40_-C41_) • Peripheral nerves and autonomic nervous system (C47_) • Connective tissue and other soft tissues (C49_) • Skin (C44) | | | | | Multiple** |

Other Sites Multiple Primary Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|-------------|-------------|--|-----------------------------------|--|---|----------------|
| M13 | | Frank in situ or malignant adenocarcinoma and an in situ or malignant tumor in a polyp | | | | Single* |
| M14 | | Multiple in situ and/or malignant polyps | | | <i>Note:</i> Includes all combinations of adenomatous, tubular, villous, and tubulovillous adenomas or polyps. | Single* |
| M15 | | | More than 60 days after diagnosis | An invasive tumor following an in situ tumor | <i>1:</i> The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. <i>2:</i> Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. | Multiple** |

Other Sites Multiple Primary Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Site | Histology | Timing | Behavior | Notes/Examples | Primary |
|------|---|--|--------|----------|--|------------|
| M16 | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and another is a specific histology; or • Carcinoma, NOS (8010) and another is a specific carcinoma; or • Squamous cell carcinoma, NOS (8070) and another is a specific squamous cell carcinoma; or • Adenocarcinoma, NOS (8140) and another is a specific adenocarcinoma; or • Melanoma, NOS (8720) and another is a specific melanoma; or • Sarcoma, NOS (8800) and another is a specific sarcoma | | | | Single* |
| M17 | | Histology codes are different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number | | | | Multiple** |
| M18 | Does not meet any of the above criteria | | | | When an invasive lesion follows an in situ within 60 days, abstract as a single primary. | Single* |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|--|--|--------------|-----------|----------|--|---|
| SINGLE TUMOR: IN SITU ONLY (Single Tumor; all parts are in situ) | | | | | | |
| H1 | The pathology/cytology report is not available | | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician’s reference to type of cancer (histology) in the medical record <p>2: Code the specific histology when documented.</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H2 | | | One type | | <p>Do not code terms that do not appear in the histology description.</p> <p>Example: Do not code squamous cell carcinoma non-keratinizing unless the words “non-keratinizing” actually appear in the diagnosis.</p> | The histology |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|--------------|---|----------|---|---|
| H3 | | | <p>The final diagnosis is</p> <ul style="list-style-type: none"> • Adenocarcinoma in a polyp or • Adenocarcinoma and a residual polyp or polyp architecture is recorded in other parts of the pathology report. • Adenocarcinoma and there is reference to a residual or pre-existing polyp or • Mucinous/colloid or signet ring cell adenocarcinoma in a polyp or <p>There is documentation that the patient had a polypectomy</p> | | It is important to know that the adenocarcinoma originated in a polyp | <p>8210 (adenocarcinoma in adenomatous polyp) or 8261 (adenocarcinoma in villous adenoma) or 8263 (adenocarcinoma in tubulovillous adenoma)</p> |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|--------------------------------------|--------------|---|----------|--|---|
| H4 | | | <ul style="list-style-type: none"> • Carcinoma in situ, NOS (8010) and a specific in situ carcinoma or • Squamous cell carcinoma in situ, NOS (8070) and a specific in situ squamous cell carcinoma or • Adenocarcinoma in situ, NOS (8140) and a specific in situ adenocarcinoma or • Melanoma in situ, NOS (8720) and a specific in situ melanoma | | The specific histology may be identified as type, subtype, predominantly, with features of, major, or with ____ differentiation, architecture or pattern. The terms architecture and pattern are subtypes only for in situ cancer. | The most specific histologic term |
| H5 | | | <ul style="list-style-type: none"> • Multiple specific histologies or • A non-specific histology with multiple specific histologies | | The specific histology may be identified as type, subtype, predominantly, with features of, major, or with ____ differentiation, architecture or pattern. The terms architecture and pattern are subtypes only for in situ cancer. | The appropriate combination/ mixed code (Table 2) |
| H6 | None of the above conditions are met | | | | | The numerically higher ICD-O-3 code |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|--|--|--------------|-----------|----------------------|---|--|
| SINGLE TUMOR: INVASIVE AND IN SITU (Single Tumor; in situ and invasive components) | | | | | | |
| H7 | | | | Invasive and in situ | This is a change from the previous histology coding rules and is different from ICD-O-3 rules. This change was made in collaboration with the ICD-O-3 editors. The consensus was that coding the invasive component of the tumor better explains the likely disease course and survival category. | The single invasive histology. Ignore the in situ terms. |
| SINGLE TUMOR: INVASIVE ONLY (Single Tumor; all parts are invasive) | | | | | | |
| H8 | No pathology/cytology specimen or the pathology/cytology report is not available | | | | 1: Priority for using documents to code the histology <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT, PET or MRI scans 2: Code the specific histology when documented 3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented | The histology documented by the physician |
| H9 | None from primary site | | | | Code the behavior /3 | The histology from a metastatic site |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|--------------|--|----------|--|---|
| H10 | | Prostate | Acinar (adeno)carcinoma | | | 8140 (adenocarcinoma NOS) |
| H11 | | | One type | | <p>1: Do not code terms that do not appear in the histology description.</p> <p>Example: Do not code squamous cell carcinoma non-keratinizing unless the words “non-keratinizing” actually appear in the diagnosis.</p> <p>2: If this is a papillary carcinoma of the thyroid, go to Rule H14</p> | The histology |
| H12 | | | <p>Final diagnosis is:</p> <ul style="list-style-type: none"> • Adenocarcinoma in a polyp or • Adenocarcinoma and a residual polyp or polyp architecture is recorded in other parts of the pathology report or • Adenocarcinoma and there is reference to a residual or pre-existing polyp or • Mucinous/colloid or signet ring cell adenocarcinoma in a polyp or <p>There is documentation that the patient had a polypectomy</p> | | It is important to know that the adenocarcinoma originated in a polyp | <p>8210 (adenocarcinoma in adenomatous polyp) or</p> <p>8261 (adenocarcinoma in villous adenoma) or</p> <p>8263 (adenocarcinoma in tubulovillous adenoma)</p> |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|--------------|---|----------|---|--|
| H13 | | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology or • Carcinoma, NOS (8010) and a more specific carcinoma or • Squamous cell carcinoma, NOS (8070) and a more specific squamous cell carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Melanoma, NOS (8720) and a more specific melanoma or • Sarcoma, NOS (8800) and a more specific sarcoma | | <p>The specific histology may be identified as type, subtype, predominantly, with features of, major, or with _____differentiation. The terms architecture and pattern are subtypes only for in situ cancer.</p> <p>Example 1: Adenocarcinoma, predominantly mucinous. Code mucinous adenocarcinoma (8480).</p> <p>Example 2: Non-small cell carcinoma, papillary squamous cell. Code papillary squamous cell carcinoma (8052).</p> | The most specific histologic term |
| H14 | | Thyroid | Papillary carcinoma | | | 8260 (papillary adenocarcinoma, NOS) |
| H15 | | Thyroid | Follicular and papillary carcinoma | | | 8340 (Papillary carcinoma, follicular variant) |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|--------------------------------------|--------------|---|----------|--|--|
| H16 | | | <ul style="list-style-type: none"> • Multiple specific histologies or • A non-specific histology with multiple specific histologies | | <p>The specific histology may be identified as type, subtype, predominantly, with features of, major or with _____ differentiation.</p> <p>Example 1 (multiple specific histologies): Mucinous and papillary adenocarcinoma. Code 8255 (adenocarcinoma with mixed subtypes).</p> <p>Example 2 (multiple specific histologies): Combined small cell and squamous cell carcinoma. Code 8045 (combined small cell carcinoma)</p> <p>Example 3 (non-specific with multiple specific histologies): Adenocarcinoma with papillary and clear cell features. Code 8255 (adenocarcinoma with mixed subtypes)</p> | The appropriate combination code (Table 2) |
| H17 | None of the above conditions are met | | | | | The numerically higher ICD-O-3 code |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|---|--|---|---|----------|---|--|
| MULTIPLE TUMORS ABSTRACTED AS A SINGLE PRIMARY | | | | | | |
| H18 | No pathology/cytology specimen or the pathology/cytology report is not available | | | | <p>1: Priority for using documents to code the histology</p> <ul style="list-style-type: none"> • Documentation in the medical record that refers to pathologic or cytologic findings • Physician's reference to type of cancer (histology) in the medical record • CT, PET or MRI scans <p>2: Code the specific histology when documented</p> <p>3: Code the histology to 8000 (cancer/malignant neoplasm, NOS) or 8010 (carcinoma, NOS) as stated by the physician when nothing more specific is documented</p> | The histology documented by the physician |
| H19 | None from primary site | | | | Code the behavior /3 | The histology from a metastatic site |
| H20 | | Prostate | Acinar (adeno)carcinoma | | | 8140 (adenocarcinoma NOS) |
| H21 | | Sites such as: Vulva Vagina Anus | Squamous intraepithelial neoplasia grade III such as: <ul style="list-style-type: none"> • vulva (VIN III) • vagina (VAIN III) • anus (AIN III). | In situ | <p>1: VIN, VAIN, and AIN are squamous cell carcinomas. Code 8077 cannot be used for glandular intraepithelial neoplasia such as prostatic intraepithelial neoplasia (PIN) or pancreatic intraepithelial neoplasia (PAIN).</p> <p>2: This code may be used for reportable-by-agreement cases</p> | 8077/2 (Squamous intraepithelial neoplasia, grade III) |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|----------------------------------|---|----------|--|--|
| H22 | | Sites such as: Pancreas | Glandular intraepithelial neoplasia grade III such as: <ul style="list-style-type: none"> • pancreas (PAIN III) | In situ | This code may be used for reportable-by-agreement cases such as intraepithelial neoplasia of the prostate (PIN III) | 8148/2 (Glandular intraepithelial neoplasia grade III) |
| H23 | | | One type | | Do not code terms that do not appear in the histology description. <i>Example:</i> Do not code squamous cell carcinoma non-keratinizing unless the words “non-keratinizing” actually appear in the diagnosis. | The histology |
| H24 | | Anus Perianal region Vulva | Extramammary Paget disease and an underlying tumor | | | The histology of the underlying tumor |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|--------------|--|----------|---|--|
| H25 | | | Final diagnosis is: <ul style="list-style-type: none"> • Adenocarcinoma in a polyp or • Adenocarcinoma and a residual polyp or polyp architecture is recorded in other parts of the pathology report or • Adenocarcinoma and there is reference to a residual or pre-existing polyp or • Mucinous/colloid or signet ring cell adenocarcinoma in a polyp or There is documentation that the patient had a polypectomy | | It is important to know that the adenocarcinoma originated in a polyp | 8210 (adenocarcinoma in adenomatous polyp) or 8261 (adenocarcinoma in villous adenoma) or 8263 (adenocarcinoma in tubulovillous adenoma) |
| H26 | | Thyroid | Papillary carcinoma | | | 8260 (papillary adenocarcinoma, NOS) |
| H27 | | Thyroid | Follicular and papillary carcinoma | | | 8340 (Papillary carcinoma, follicular variant) |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------|-----------------------------|--------------|---|----------------------|---|---|
| H28 | | | | Invasive and in situ | This is a change from the previous histology coding rules and is different from ICD-O-3 rules. This change was made in collaboration with the ICD-O-3 editors. The consensus was that coding the invasive component of the tumor better explains the likely disease course and survival category. | The single invasive histology. Ignore the in situ terms |
| H29 | | | <ul style="list-style-type: none"> • Cancer/malignant neoplasm, NOS (8000) and a more specific histology or • Carcinoma, NOS (8010) and a more specific carcinoma or • Squamous cell carcinoma, NOS (8070) and a more specific squamous cell carcinoma or • Adenocarcinoma, NOS (8140) and a more specific adenocarcinoma or • Melanoma, NOS (8720) and a more specific melanoma or • Sarcoma, NOS (8800) and a more specific sarcoma | | <p>The specific histology may be identified as type, subtype, predominantly, with features of, major, or with _____differentiation. The terms architecture and pattern are subtypes only for in situ cancer.</p> <p>Example 1: Adenocarcinoma, predominantly mucinous. Code mucinous adenocarcinoma (8480).</p> <p>Example 2: Non-small cell carcinoma, papillary squamous cell. Code papillary squamous cell carcinoma (8052).</p> | The most specific histologic term |

Other Sites Histology Coding Rules – Matrix
Excludes Head and Neck, Colon, Lung, Melanoma, Breast,
Kidney, Renal Pelvis, Ureter, Bladder, Brain, Lymphoma and Leukemia

| Rule | Pathology/Cytology Specimen | Primary Site | Histology | Behavior | Notes and Examples | Code |
|------------|--------------------------------------|--------------|---|----------|---|--|
| H30 | | | Multiple specific histologies or A non-specific histology with multiple specific histologies | | <p>The specific histologies may be identified as a type, subtype, predominantly, with features of, major, or with ____ differentiation.</p> <p>Example 1 (multiple specific histologies): Gyn malignancy with mucinous, serous and papillary adenocarcinoma. Code 8323 (mixed cell adenocarcinoma)</p> <p>Example 2 (multiple specific histologies): Combined small cell and squamous cell carcinoma. Code 8045 (combined small cell carcinoma).</p> <p>Example 3 (non-specific with multiple specific histologies): Adenocarcinoma with papillary and clear cell features. Code 8255 (adenocarcinoma with mixed subtypes)</p> | The appropriate combination/mixed code (Table 2) |
| H31 | None of the above conditions are met | | | | | The numerically higher ICD-O-3 code |